FOR IMMEDIATE RELEASE
CHICAGO, IL, June 1, 2003 - Amgen (Nasdaq:AMGN), the world´s largest biotechnology company, presented data on Aranesp?? (darbepoetin alfa) dosed once every two weeks and once every three weeks in the management of anemia in patients with chemotherapy-induced anemia. Results from seven studies, including the large-scale SOAR (Successful Outcomes in Anemia Research) trial, further enhance the wide body of data supporting the benefits of extended dosing with Aranesp?? compared to other currently available anemia treatments.